TNFSF11 and diabetes mellitus: In addition, the expression levels of proinflammatory cytokines including TNF-α and RANKL are also upregulated in diabetes mellitus, causing more bone loss [51,52,53]; therefore, (D-Ala2)GIP may serve as an alternative treatment for osteoporosis in diabetic patients, as well as those with inflammatory bone diseases accompanying diabetes.